Solubilizer and external preparations containing the same

TECHNICAL FIELD
The present invention relates to a solubilizing agent or solubilizer for a pharmaceutically effective ingredient and an external preparation containing the solubilizer. In particular, the present invention relates to a solubilizer for an efficacious ingredient used in a percutaneously absorbable preparation such as poultice or for a fat-soluble powder used in a pack, the solubilizer being excellent in solubilization of such an effective ingredient as well as in safety, stability, compatibility, non-odorousness and refreshing, effect, and also relates to an external preparation containing the solubilizer.
BACKGROUND ART
Up to this time, many attempts have been made to attain desirable curative effects by the percutaneous absorption of drugs. It is a significant problem in such percutaneously absorbable preparations how efficiently the drug (active ingredient as a drug) is released from the base, i.e., how efficiently the drug migrates from the base to the skin. In general, when attempting to design a preparation using some drug therein, there frequently occurs a case that the drug crystallizes in the base because of its insufficient dissolution therein, resulting in poor drug release so that a sufficient curative effect is not achieved. Accordingly, the selection of an optimum solubilizer for a drug is an important factor in designing such a preparation. If an unsuitable solubilizer is selected for a drug, the release of the drug from the base is lowered due to the insufficient dissolution of the drug in the base, which leads to poor migration of the drug to an affected part so that poor curative effect results.
Solubilizers currently used for drugs include alcohols, glycols, several surfactants, essential oils such as peppermint oil, crotamiton, methyl salicylate, glycol salicylate and fatty acid esters such as isopropyl myristate.
For example, Japanese Pat. Appln. Laid-Open Gazette No. 154413/1981 discloses an anti-inflammatory agent for external use which comprises both an oil-in-water emulsion containing a solution of flurbiprofen in a terpene or in a fatty acid ester and an aqueous base, and Japanese Pat. Appln. Laid-Open Gazette No. 98209/1982 discloses another anti-inflammatory agent for external use which is prepared by dissolving indomethacin in a mono- or polyhydric alcohol or the like.
However, these solubilizers have problems because they have poor solubilizability (capability of solubilization) to cause the crystallization of a drug, they are limited in use due to their odors, they bleed from the base with the lapse of time due to their poor compatibility with the base, they are poor in stability to cause decomposition or discoloration with the lapse of time and they cause undesirable side effects due to their stimuli to the skin, resulting in unsatisfactory effects in many cases.
Meanwhile, attempts have been made to get a powder which is soluble in fat or difficultly soluble in water (hereinafter referred to as "fat-soluble powder") to be contained in a pack for its practical use. However, a pack generally comprises a water-soluble base which exhibits extremely poor solubilizability for a fat-soluble powder, so that many of the above attempts were accompanied by the problems that the solubilization of the powder in the base was difficult and/or that the resulting pack was poor in stability to cause crystallization of the powder with the lapse of time even when the powder could be solubilized in the base in the preparation stage.
SUMMARY OF THE INVENTION
The present invention aims at solving the above problems to provide a solubilizer which exhibits excellent solubilizability for a pharmaceutically effective ingredient and is excellent in safety, stability and compatibility, and provides an external preparation containing the solubilizer.
The above object of the present invention can be attained by using 3-l-menthoxypropane-1,2-diol as the solubilizer for a pharmaceutically effective ingredient.
Namely, the present invention resides in a solubilizer for a pharmaceutically effective ingredient which is composed of 3-l-menthoxypropane-1,2-diol, and in an external preparation containing the solubilizer and a pharmaceutically effective ingredient.
The term "pharmaceutically effective ingredient" used in this specification refers to a drug used in a percutaneously absorbable preparation or a fat-soluble powder used in a pack.
3-l-menthoxypropane-1,2-diol which is the solubilizer of the present invention, is a known substance described in, e.g., Japanese Pat. Appln. Laid-Open Gazette No. 88334/1983 as a substance having a cooling or refreshing activity. Further, Japanese Pat. Appln. Laid-Open Gazette No. 25908/1985 discloses that this compound is useful as a cosmetic material, has an excellent cooling effect and is extremely safe for the skin. However, there has not been made even any attempt to solubilize a pharmaceutically effective ingredient such as a drug by using said known substance, to say nothing of an attempt to get a drug solubilized by use of this substance to be absorbed percutaneously. In other words, such an attempt has been made for the first time by the inventors of the present invention and the present invention is based on this entirely new finding.
According to the present invention, the amount of 3-l-menthoxypropane-1,2-diol contained in an external preparation is 0.001 to 20% by weight of the total amount of the external preparation.
In particular, when the external preparation is a percutaneously absorbable preparation containing a drug as the effective ingredient and 3-l-menthoxypropane-1,2-diol is used as a solubilizer, the amount of 3-l-menthoxypropane-1,2-diol used will be 0.1 to 20% by weight, preferably 0.5 to 10% by weight, of the total amount of the external preparation. When the amount is less than 0.1% by weight, no sufficient effects as the solubilizer will be exhibited, while when it exceeds 20% by weight, no stable preparation will be prepared.
The drug to be used in the percutaneously absorbable preparation which is one of the external preparations according to the present invention is not particularly limited but may be any one selected from among known conventional drugs. Such drugs include steroidal anti-inflammatory agents such as prednisolone, dexamethasone, hydrocortisone, fluocinolone acetonide, betamethasone valerate, betamethasone dipropionate, clobetasone butyrate and prednisolone succinate; nonsteroidal anti-inflammatory agents such as indomethacin, diclofenac, ibuprofen, ketoprofen, flufenamic acid, ketorolac, flurbiprofen, felbinac, suprofen, pranoprofen, tiaprofen, loxoprofen and tenidap, and their ester derivatives; antiallergic agents such as tranilast, azelastine, ketotifen, ibudilast and emedastine; antihistamic agents such as diphenhydramine, chlorpheniramine, promethazine and tripelennamihe; central nervous system stimulants such as chlorpromazine, nitrazepam, diazepam, phenobarbital and reserpine; hormones such as insulin, testosterone, norethisterone, methyltestosterone, progesterone and estradiol; antihypertensive agents such as clonidine, reserpine and guanethidine sulfate; cardiotonics such as digitoxin and digoxin; antiarrhythmic agents such as propranolol hydrochloride, procainamide hydrochloride, ajimalin, pindolol and tulobuterol hydrochloride; coronary vasodilators such as nitroglycerin, isosorbide dinitrate, papaverine hydrochloride and nifedipine; local anesthetics such as lidocaine, benzocaine, procaine hydrochloride and tetracaine; analgetic agents such as morphine, aspirin, codeine, acetanilide and aminopyrine; skeletal muscle relaxants such as eperisone, tizanidine, tolperisone and inaperisone; antifungal agents such as acetophenylamine, nitrofurazone, pentamycin, naphthiomate, miconazole, omoconazole, clotrimazole, butenafine hydrochloride and bifonazole; antineoplastic agents such as 5-fluorouracil, busulfan, actinomycin, bleomycin and mitomycin; antidysurics such as terodiline hydrochloride and oxybutynin hydrochloride; antiepileptics such as nitrazepam and meprobamate; antiparkinson agents such as chlorzoxazone and levodopa; assistant to the prohibition of smoking such as nicotine; vitamins and prostaglandin, though the drug usable in the percutaneously absorbable preparation is of course not limited to them.
The amount of the drug used is preferably 0.001 to 20% by weight, more preferably 0.5 to 10% by weight, of the total amount of the external preparation, though it is not particularly limited.
The dosage form of the percutaneously absorbable preparation of the present invention is not particularly limited, but may be any one selected from among conventional poultice, plaster, ointment, gel, cream, gel-type cream, lotion, reserver-type patch, liniment, aerosol and so forth.
The poultice and plaster according to the present invention will now be described below.
In preparing the poultice, a hydrophilic base comprising a water-soluble polymer, a polyhydric alcohol and water is used in consideration of long-term stability, releasability, percutaneous absorbability and safety for the skin.
The water-soluble polymer to be used in the hydrophilic base may be one or more members suitably selected from the group consisting of gelatin, casein, pullulan, dextran, sodium alginate, soluble starch, carboxystarch, dextrin, carboxymethylcellulose, sodium carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, polyvinyl alcohol, polyethylene oxide, polyacrylic acid, polyacrylamide, polysodium acrylate, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl ether, methoxyethylene-maleic anhydride copolymer, isobutylenemaleic anhydride copolymer, N-vinylacetamide, copolymer comprising N-vinylacetamide and acrylic acid and/or acrylate salt and so forth. The amount of the water-soluble polymer used is 1 to 30% by weight, preferably 1 to 20% by weight, more preferably 1 to 15% by weight, based on the total amount of the preparation. When the amount is less than 1% by weight, the resulting preparation will have too low a viscosity to retain its shape, while when it exceeds 30% by weight, the resulting mixture of the constituents will have a high viscosity to lower the workability in preparing a homogeneous dispersion of the constituents or in applying the dispersion.
The polyhydric alcohol is one or more members suitably selected from the group consisting of polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, isobutylene glycol, glycerol, diglycerol, sorbitol and so forth. The amount of the polyhydric alcohol used is 10 to 90% by weight, preferably 10 to 70% by weight, more preferably 20 to 60% by weight. When the amount is less than 10% by weight, the resulting preparation will exhibit poor humectant effect, while when it exceeds 90% by weight, the solubility of the water-soluble polymer will be adversely affected. The amount of water used is 10 to 90% by weight, preferably 20 to 80% by weight. The water serves to solubilize the water-soluble polymer to thereby make the polymer develop its thickening, cohesive and shape-retaining properties.
If necessary, the base of the poultice may further contain one or more crosslinking agents in addition to the above essential components. The crossliking agents include polyvalent metal compounds such as aluminum hydroxide, aluminum chloride, calcium hydroxide, calcium chloride, aluminum sulfate, aluminum ammonium sulfate, aluminum potassium sulfate, magnesium aluminometasilicate and dihydroxyaluminum aminoacetate; and compounds each having at least two epoxy groups in the molecule such as ethylene glycol diglycidyl ether, polyethylene glycol diglycidyl ether, propylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, glycerol polyglycidyl ether, polyglycerol polyglycidyl ether, sorbitol polyglycidyl ether, sorbitan polyglycidyl ether, trimethylolpropane polyglycidyl ether, pentaerythritol polyglycidyl ether, resorcinol diglycidyl ether, neopentyl glycol diglycidyl ether and 1,6-hexanediol diglycidyl ether.
Further, the base of the poultice may contain one or more additives suitably selected from among fillers such as kaolin, zinc oxide, titanium dioxide, talc, bentonite and synthetic aluminum silicate; antiseptics such as thymol, methyl paraben and ethyl paraben; antioxidants such as ascorbic acid, stearic esters, dibutylhydroxytoluene, butylhydroxyanisole, gallic esters, vitamin E, vitamin E acetate and disodium edetate; ultraviolet absorbers such as 2-hydroxy-4-methoxybenzophenone, ethyl p-aminobenzoate, 2-(2-hydroxy-5-methylphenyl)benzotriazole, glycol salicylate, methyl salicylate and phenyl salicyalte; and emulsifying agents such as fatty acid esters of sorbitan, fatty acid esters of glycerol, fatty acid esters of decaglycerol, fatty acid esters of polyoxyethylene sorbitan, fatty acid esters of polyethylene glycol and polyoxyethylene alkyl ethers.
It is essential that the support of the poultice is made of a material which has no influence on the release of a drug, i.e., that the support neither interacts with a drug nor adsorb a drug. The support is selected from the group consisting of films and sheets of polyethylene, polypropylene, polyvinyl chloride, polyester, nylon and polyurethane; porous materials, expanded materials and woven and nonwoven fabrics of these polymers; laminates each comprising one or more members selected from the group consisting of these films and sheets and one or more members selected from the group consisting of these materials and fabrics and so forth. The release sheet of the poultice according to the present invention may be selected from the group consisting of films of polyethylene, polypropylene and polyester; products of release treatment of these films with silicone compounds; release paper and so forth.
The preparation of the poultice will now be described, though the poultice can be easily prepared by known processes.
For example, a nonsteroidal anti-inflammatory agent selected from the group consisting of diclofenac, ketoprofen, flurbiprofen, tenidap, loxoprofen, ketorolac, felbinac, suprofen, indomethacin and ester derivatives and salts of these drugs is solubilized in 3-l-menthoxypropane-1,2-diol to form a solution (A) which may, if necessary, be incorporated with one or more additives selected from the group consisting of a stabilizer, an antioxidant, an ultraviolet absorber, an emulsifying agent, an antiseptic, an antimicrobial and so forth. Separately, a water-soluble polymer is mixed into, dispersed and solubilized in a polyhydric alcohol or water to form a homogeneous paste (B). The solution (A) is added to the paste (B) to form a homogeneous dispersion. This dispersion is spread directly on a support, or alternatively it is once spread on a paper or film treated with a releasing agent and thereafter transferred to a support by pressing. Thus, a poultice according to the present invention is prepared. The above-mentioned procedure for mixing base materials, a drug and other components is just one example, not limiting the procedure for preparing the poultice according to the present invention.
The plaster according to the present invention comprises, for example, (a) a nonsteroidal anti-inflammatory agent selected from the group consisting of diclofenac, ketoprofen, flurbiprofen, tenidap, loxoprofen, ketorolac, felbinac, suprofen and ester derivatives and salts of these drugs, (b) a solubilizer comprising a rosin ester derivative and 3-l-menthoxypropane-1,2-diol, (c) a styrene-isoprene-styrene block copolymer or an acrylic adhesive as the base polymer and (d) a softening agent or a known plaster base.
The support for the plaster is selected from among polypropyene fabrics and polyester fabrics which have no influence on the release of a nonsteroidal anti-inflammatory agent. The polyester fabric to be used as the support is preferably one made of polyethylene terephthalate (PET) or polybutylene terephthalate (PBT). In order to attain excellent release of a nonsteroidal anti-inflammatory agent, it is essential that the support neither interacts with a nonsteroidal anti-inflammatory agent nor adsorb it. From this standpoint, the optimum polymer constituting the support is polypropylene, PET or PBT. The use of a support made of polypropylene, FET or PBT prevents the adsorption of a drug to the support to enable excellent release of the drug.
The plaster according to the present invention is provided with such stretchability that the average stresses at 50% elongation in lengthwise and widthwise directions each is 0.3 kg/cm or below, so that it can be applied to a bend of human skin. By virtue of this stretchability, the plaster according to the present invention not only is capable to be used expediently and to follow the move of the skin so that the friction and pressure during the use of the plaster on the skin decreases, thus causing little side effects such as contact dermatitis.
The plaster according to the present invention is characterized by using a mixture comprising a rosin ester derivative, which is well known by those skilled in the art as a tackifier resin, and 3-l-menthoxypropane-1,2-diol at a specific ratio so as to attain excellent solubility of a drug surprisingly. Further, the use of this mixture improves the release of a drug remarkably. In order to attain more excellent solubility of a drug such as a nonsteroidal anti-inflammatory agent in the base and more excellent release thereof from the base, it is preferable that a nonsteroidal anti-inflammatory agent, a rosin ester derivative and 3-l-menthoxypropane-1,2-diol be contained at a weight ratio of 1:(2 to 25:(1 to 10). When these components are contained at such a ratio as above, the drug exhibits high solubility and releasability.
The term "rosin ester derivative" used in this specification refers to any of the products prepared by esterifying various rosins and subjecting the obtained esters to hydrogenation or purification. The esters include methyl ester, glycerol ester and pentaerythritol ester. The rosin ester derivatives include Ester Gum A, AA-G, H and HP (trade names, products of Arakawa Chemical Industry Co, LTD.), Hariester-L, S and P (trade names, products of Harima Chemicals, Inc.), Super Ester A-75 (trade name, a product of Arakawa Chemical Industry Co., Ltd.), KE-311 (trade name, a product of Arakawa Chemical Industry Co., Ltd.), Hercolyn D (trade name, a product of Hercules Inc.) and Foral 85 and 105 (trade names, products of Hercules Inc.).
The base polymer of the plaster may be selected from conventional ones in consideration of safety For the skin, releasability of a drug and adhesion to the skin. From the standpoint of the release characteristics of a nonsteroidal anti-inflammatory agent, it is preferable that the base polymer be a styrene-isoprene-styrene block copolymer having a particularly low polarity. Such block copolymers include Cariflex TR-1107, TR-1111, TR-1112 and TR-1117 (trade names, products of Shell Chemical) and Solprene 428 (trade name, a product of Phillips Petroleum). These styrene-isoprene-styrene block copolymers may be each used together with other polymer such as polyisobutylene. Vistanex (trade name, a product of Exxon Kagaku) is preferably used as the polyisobutylene.
The softening agent serves to plasticize or soften the styrene-isoprene-styrene block copolymer used as the base polymer to keep the adhesion of the plaster to the skin at a proper level. The softening agent may be selected from the group consisting of almond oil, olive oil, camellia oil, persic oil, peanut oil, liquid paraffin and so forth. The amount of the softening agent used is preferably 150 to 350 parts by weight per 100 parts by weight of the styrene-isoprene-styrene block copolymer.
The content of a drug is preferably 70 to 1200 .mu.g/cm.sup.2 from the standpoints of therapeutically effective release of a drug and availability thereof, though it is not particularly limited. Preferable proportions of a drug, rosin ester derivative, 3-l-menthoxypropane-1,2-diol, styrene-isoprene-styrene block copolymer and softening agent are as follows.
That is, the plaster comprises 0.5 to 10% by weight of a drug, 5 to 70% by weight of a rosin ester derivative, 0.5 to 10% by weight of 3-l-menthoxypropane-1,2-diol, 5 to 40% by weight of a styrene-isoprene-styrene block copolymer and 10 to 75% by weight of a softening agent, each percentage being based on the total amount.
The plaster according to the present invention can be easily prepared by known processes. For example, it can be prepared by mixing a styrene-isoprene-styrene block copolymer with a softening agent and a rosin ester derivative under heating at 120.degree. to 160.degree. C. by the use of a mixing machine such as kneader or mixer, adding a drug and 3-l-menthoxypropane-1,2-diol to the obtained mixture, and applying the resulting mixture to a support either by spreading the mixture directly on a woven or nonwoven fabric of polypropylene or polyester or by spreading the mixture on a paper or film treated with a releasing agent and thereafter transferring the spread mixture to a desired support by pressing.
Now, brief description will be made of other percutaneously absorbable preparations (such as ointment, gel, cream, gel-type cream, lotion, reserver-type patch, liniment and aerosol) according to the present invention.
The ointment according to the present invention comprises at least higher fatty acid such as myristic acid or an ester thereof, a wax such as spermaceti, a surfactant such as polyoxyethylene and a hydrocarbon such as hydrophilic vaseline in addition to a drug and 3-l-menthoxypropane-1,2-diol.
The ointment can be prepared by, for example, mixing 5 to 15% by weight of a higher fatty acid or an ester thereof with 1 to 10% by weight of a surfactant, 0.5 to 10% by weight of a drug and 0.5 to 10% by weight of 3-l-menthoxypropane-1,2-diol either at room temperature or under heating, adding 4 to 10% by weight of a wax and 50 to 90% by weight of a hydrocarbon to the obtained mixture, heating or heat-melting the resulting mixture, keeping the mixture at 50.degree. to 100.degree. C. to make the whole mixture a transparent solution, homogenating the solution with a homomixer, and lowering the temperature of the resulting solution to room temperature under stirring.
The gel according to the present invention comprises at least a lower alcohol (such as ethanol), water, a gelling agent (such as carboxyvinyl polymer) and a neutralizing agent (such as triethanolamine) in addition to a drug and 3-l-menthoxypropane-1,2-diol.
The gel can be prepared, for example, as follows: 0.5 to 5% by weight of a gelling agent is swollen with at most 55% by weight of water; separately, 0.5 to 10% by weight of a drug is solubilized in 0.5 to 10% by weight of 3-l-menthoxypropane-1,2-diol and the obtained solution is further solubilized in a mixture comprising at most 40% by weight of a glycol and at most 60% by weight of a lower alcohol; the obtained solution is mixed with the gelling agent swollen above; and the resulting mixture is adjusted to pH 4-7 by the addition of a neutralizing agent, thus forming a gel according to the present invention.
The cream according to the present invention comprises at least a higher fatty acid ester such as a myristate, water, a hydrocarbon such as liquid paraffin) and an emulsifying agent such as polyoxyethylene alkyl ether in addition to a drug and 3-l-menthoxypropane-1,2-diol.
The cream can be prepared by stirring a mixture comprising a drug, 3-l-menthoxypropane-1,2-diol, a higher fatty acid ester, water, a hydrocarbon and an emulsifying agent in proper amounts.
A gel-type cream has intermediate properties between a gel and a cream and can be prepared by adding a gelling agent such as a carboxyvinyl polymer to components of cream as described above and adjusting the resulting mixture to pH 4-8, preferably pH 5-6.5 by the addition of a neutralizing agent such as diisopropanolamine.
The gel-type cream according to the present invention can be prepared, for example, as follows: 0.5 to 10% by weight of a drug is solubilized in 0.5 to 10% by weight of 3-l-menthoxypropane-1,2-diol and the obtained solution is further solubilized in a mixture comprising at most 25% by weight of a higher fatty acid ester and at most 40% by weight of a lower alcohol, followed by the addition of at most 5% by weight of an emulsifying agent; separately, 0.5 to 5% by weight of a gelling agent is swollen with water; the swollen agent is mixed with the solution prepared above; and the obtained mixture is homogenized with a homomixer and adjusted to pH 4-8 by the addition of a neutralizing agent.
The lotion according to the present invention comprises at least a lower alcohol such as ethanol and water and/or a glycol in addition to a drug and 3-l-menthoxypropane-1,2-diol.
The lotion can be prepared by stirring a mixture comprising a drug, 3-l-menthoxypropane-1,2-diol, a lower alcohol and water and/or a glycol in proper amounts.
The reserver-type patch according to the present invention comprises at least (1) a backing layer, (2) a drug reserving layer, (3) a drug releasing layer and (4) a pressure-sensitive adhesive layer, wherein the base of the drug reserving layer (2) comprises one mixture selected from the group consisting of
(a) mixture comprising at least a glycol, a lower alcohol, water and a water-soluble polymer,
(b) a mixture comprising at least an aliphatic alcohol and a polyhydric alcohol and
(c) a mixture comprising at least a paraffin and a silicon compound,
in addition to a drug and 3-l-menthoxypropane-1,2-diol.
The liniment according to the present invention comprises at least an alcohol such as ethanol or polyethylene glycol, water and an ester of fatty acid such as adipic acid or sebacic acid in addition to a drug and 3-l-menthoxypropane-1,2-diol.
The liniment can be prepared by dissolving 0.5 to 10% by weight of a drug in 0.5 to 10% by weight of 3-l-menthoxypropane-1,2-diol and mixing the obtained solution with 10 to 70% by weight of an alcohol, at most 55% by weight of water and at most 60% by weight of a fatty acid ester under stirring.
The aerosol according to the present invention comprises at least a lower alcohol, water and dimethyl ether and/or liquefied petroleum gas in addition to a drug and 3-l-menthoxypropane-1,2-diol, and may further contain an auxiliary drug such as camphor .alpha.-tocopherol or menthol as needed.
The aerosol can be prepared by dissolving 0.5 to 10% by weight of a drug in 0.5 to 10% by weight of 3-l-menthoxypropane-1,2-diol, adding a lower alcohol and water to the obtained solution, charging the obtained mixture into an aerosol container and injecting dimethyl ether and/or liquefied petroleum gas as a propellant into the container.
The percutaneously absorbable preparations according to the present invention may further contain various pharmacologically acceptable additives, so far as the object of the present invention is not marred. Examples of such additives include a stabilizer, an antioxidant, a perfume, a filler, an ultraviolet absorber, an antihistamine, an antiseptic, an antimicrobial agent and an absorbefacient.
Then, the pack according to the present invention will be described. The pack according to the present invention is characterized by using 3-l-menthoxypropane-1,2-diol as the solubilizer for a fat-soluble powder used as the pharmaceutically effective ingredient.
The term "fat-soluble powder" used in this specification refers to a powder which is insoluble or difficultly soluble in water, and such a powder includes pharmaceutically effective ingredients and various additives used in the preparation of the pack. In particular, it is preferable that the powder be selected from the group consisting of glycyrrhetinic acid, stearyl glycyrrhetinate, glycyrrhizinic acid, L-ascorbyl stearate, L-ascorbyl palmitate, calciferol, cholecalciferol, pionin and isopropylmethylphenol. The use of 3-l-menthoxypropane-1,2-diol as the solubilizer for a fat-soluble powder as described above enables the stable dissolution of the powder in the base to give an odorless pack imparting comfortable refreshing refrigeration to the skin.
It is preferable that the content of 3-l-menthoxypropane-1,2-diol in the pack be in the range of 0.001 to 5% by weight. When the content is less than 0.001% by weight, no satisfactory solubilizability will be attained, while when it exceeds 5% by weight, the resulting pack will be poor in physical properties and feelings in use.
The dosage form of the pack according to the present invention is not particularly limited, but may be any conventional one selected from the group consisting of face cleasing packs of creamy, clayey and foam types, sheet packs of pressure-sensitive adhesive type and impregnation type, peel-off pack (of film forming type) and so forth. Of course, the pack may further contain a conventional filler, perfume or the like at need.

BRIEF DESCRIPTION OF DRAWING
FIGURE 1 is a graph showing the human absorption rates of the plasters of Example 9 and Comparative Example 6.

DESCRIPTION OF PREFERRED EMBODIMENTS
The present invention will be better understood by Examples which should not be construed as limiting the invention, in comparison with Comparative Examples.
______________________________________Example 1 poultice______________________________________(A) 3-l-menthoxypropane-1,2-diol 1.0% by weight diclofenac 0.5% by weight(B) purified water 48.5% by weight gelatin 8.0% by weight kaolin 1.0% by weight glycerol 35.0% by weight polysodium acrylate 2.0% by weight polyvinyl alcohol 3.0% by weight aluminum hydroxide 1.0% by weight______________________________________
The above ingredients were solubilized together and agitated so as to obtain a homogeneous paste. The paste was applied on a polypropylene nonwoven fabric with a speader to obtain a percutaneously absorbable preparation layer having a thickness of 1 mm. Then, the preparation layer was covered with a polypropylene film and cut into pieces each having a predetermined size so as to obtain intended pharmaceutical products.
______________________________________Example 2 poultice______________________________________(A) 3-l-menthoxypropane-1,2-diol 2.0% by weight loxoprofen 1.0% by weight thymol 0.1% by weight(B) purified water 62.4% by weight gelatin 3.0% by weight titanium oxide 1.0% by weight glycerol 25.0% by weight polysodium acrylate 3.0% by weight carboxymethyl cellulose 1.0% by weight ethylene glycol diglycidyl ether 1.0% by weight sorbitan fatty acid ester 0.5% by weight______________________________________
The above ingredients were solubilized together and agitated so as to obtain a homogeneous paste. The paste was applied on a polyester nonwoven fabric with a spreader to obtain a percutaneously absorbable preparation layer having a thickness of 0.5 mm. Then, the preparation layer was covered with a polyethylene film and cut into pieces each having a predetermined size so as to obtain intended pharmaceutical products.
______________________________________Example 3 poultice______________________________________(A) 3-l-menthoxypropane-1,2-diol 3.0% by weight ibuprofen 0.5% by weight ethyl paraben 0.2% by weight(B) purified water 42.3% by weight methoxyethylene anhydrous 5.0% by weight maleic acid copolymer synthetic aluminium silicate 3.0% by weight glycerol 40.0% by weight polyacrylic acid 2.0% by weight polyvinyl alcohol 2.5% by weight calcium hydroxide 1.5% by weight______________________________________
The above ingredients were solubilized together and agitated so as to obtain a homogeneous paste. The paste was applied on a polyurethane film with a spreader to obtain a percutaneously absorbable preparation layer having a thickness of 1 mm. Then, the preparation layer was covered with a polyurethane film and cut into pieces each having a predetermined size thereby to obtain intended pharmaceutical products.
______________________________________Example 4 poultice______________________________________(A) 3-l-menthoxypropane-1,2-diol 2.0% by weight ketoprofen 0.5% by weight(B) purified water 36.0% by weight N-vinylacetamide 5.0% by weight glycerol 50.0% by weight polyacrylic acid 3.0% by weight carboxymethyl cellulose 1.0% by weight magnesium metasilicate alminate 1.5% by weight fatty acid esters of glycerol 1.0% by weight______________________________________
The above ingredients were solubilized together and agitated so as to obtain a homogeneous paste. The paste was applied on a polyester nonwoven fabric with a spreader to obtain a percutaneously absorbable preparation layer having a thickness of 1 mm. Then, the preparation layer was covered with a polyester film and cut into pieces each having a predetermined size so as to obtain intended pharmaceutical products.
______________________________________Comparative Example 1 poultice______________________________________(A) crotamiton 1.0% by weight suprofen 0.8% by weight(B) purified water 54.2% by weight gelatin 6.0% by weight bentonite 5.0% by weight glycerol 25.0% by weight sodium alginate 2.0% by weight polyethylene oxide 4.0% by weight aluminum sulfate 1.5% by weight fatty acid esters of 0.5% by weight polyethylene glycol______________________________________
The above ingredients were solubilized together and agitated thereby to obtain a homogeneous paste. The paste was applied on a polyvinyl chloride with a spreader to obtain a percutaneously absorbable preparation layer having a thickness of 0.3 mm. Then, the preparation layer was covered with a polypropylene film and cut into pieces each having a predetermined size thereby to obtain intended pharmaceutical products.
______________________________________Comparative Example 2 poultice______________________________________(A) glycerol salicylate 2.0% by weight ketoprofen 0.5% by weight(B) purified water 36.0% by weight N-vinylacetamide 5.0% by weight fatty acid esters of glycerol 1.0% by weight glycerol 50.0% by weight polyacrylic acid 3.0% by weight carboxymethyl cellulose 1.0% by weight magnesium metasilicate alminate 1.5% by weight______________________________________
The above ingredients were solubilized together and agitated thereby to obtain a homogeneous paste. The paste was applied on a polyester nonwoven fabric with a spreader to obtain a percutaneously absorbable preparation layer having a thickness of 1 mm. Then, the preparation layer was covered with a polyester film and cut into pieces each having a predetermined size thereby to obtain intended pharmaceutical products.
______________________________________Comparative Example 3 poultice______________________________________(A) butylene glycol 4.0% by weight peppermint oil 1.0% by weight loxoprofen 0.5% by weight(B) purified water 47.5% by weight gelatine 3.0% by weight kaolin 1.0% by weight glycerol 35.0% by weight polysodium acrylate 3.0% by weight carboxyvinyl polymer 2.5% by weight dextrin 2.0% by weight sorbitan polyglycidyl ether 0.5% by weight______________________________________
The above ingredients were solubilized together and agitated thereby to obtain a homogeneous paste. The paste was applied on a polypropylene nonwoven fabric with a spreader to obtain a percutaneously absorbable preparation layer having a thickness of 1 mm. Then, the preparation layer was covered with a polyester film and cut into pieces each having a predetermined size thereby to obtain intended pharmaceutical products.
______________________________________Example 5 plaster______________________________________styrene-isoprene-styrene 22.5% by weightblock copolymerpolyisobutylene 5.0% by weighttackifier (rosin ester) 15.0% by weightliquid paraffin 56.0% by weight3-l-menthoxypropane-1,2-diol 1.0% by weightketotifen 0.5% by weight______________________________________
The above components were agitated under heating, thereby obtaining a paste. The paste was spread on a foundation to obtain a tape containing ketotifen.
______________________________________Example 6 plaster______________________________________pressure-sensitive adhesive of 77.0% by weightacrylic resin solubilizer type (in terms of solids)(trade name: NISSETSU PE-300)3-l-menthoxypropane-1,2-diol 15.0% by weightisosorbide dinitrate 8.0% by weight______________________________________
The above components were mixed together to obtain a paste. The paste was spread on a foundation and then freed of the solvent by evaporation thereby to obtain a tape containing isosorbide dinitrate.
______________________________________Example 7 plaster______________________________________silicone adhesive 89.0% by weight(trade name: BIO-PSA X7-2920) (in terms of solids)3-l-menthoxypropane-1,2-diol 7.0% by weightclonidine 4.0% by weight______________________________________
The above components were agitated and mixed together to obtain a paste. The paste was spread on a foundation and then freed of the solvent by evaporation thereby to obtain a tape containing clonidine.
______________________________________Comparative Example 4 plaster______________________________________silicone adhesive 96.0% by weight(trade name: BIO-PSA X7-2920) (in terms of solids)clonidine 4.0% by weight______________________________________
The above components were mixed together under agitation to obtain a paste. The paste was spread on a foundation and then freed from the solvent by evaporation thereby to obtain a tape containing clonidine. This Comparative Example indicates a formulation which was the same as Example 7 except for 4, 3-l-menthoxypropane-1,2-diol.
______________________________________Comparative Example 5 plaster______________________________________silicone adhesive 89.0% by weight(trade name: BIO-PSA X7-2920) (in terms of solids)isopropyl myristate 7.0% by weightclonidine 4.0% by weight______________________________________
The above components were agitated and mixed together to obtain a paste. The paste was spread on a foundation and then freed of the solvent by evaporation thereby to obtain a tape containing clonidine. This Comparative Example 5 indicates a formulation which was the same as Example 7 except that isopropyl myristate was substituted for the menthoxypropane-1,2-diol used in Example 7.
______________________________________Example 8 plaster______________________________________styrene-isoprene-styrene 25.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 59.0% by weightrosin ester derivative 5.0% by weight(trade name: Ester Gum AA-G)3-l-menthoxypropane-1,2-diol 10.0% by weightdiclofenac 1.0% by weight______________________________________
The components of the above prescription were mixed by a kneader to obtain a paste. Thereafter, the paste was applied directly on a PBT woven fabric and then covered with a liner to obtain a plaster.
______________________________________Example 9 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 43.5% by weightpolyisobutylene 10.0% by weight(trade name: Vistanex)rosin ester derivative 21.5% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 4.0% by weightdiclofenac 1.0% by weight______________________________________
The components of the above prescription were mixed by a mixer to obtain a paste. The paste was applied on a plastic film previously endowed with releasability and then covered with a PET woven fabric and pressure-contact transferred to obtain a plaster.
______________________________________Example 10 plaster______________________________________styrene-isoprene-styrene 21.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 63.0% by weightrosin ester derivative 10.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 4.0% by weightdiclofenac 2.0% by weight______________________________________
The components of the above prescription were mixed together by a kneader to obtain a paste. The paste was applied on a plastic film previously endowed with releasability and, covered tereon with a PBT nonwoven fabric and pressure-contact transferred to obtain a plaster.
______________________________________Example 11 plaster______________________________________styrene-isoprene-styrene 30.0% by weightblock copolymer(trade name: Cariflex TR-1111)liquid paraffin 57.0% by weightrosin ester derivative 7.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 5.0% by weightdiclofenac 1.0% by weight______________________________________
The components of the above prescription were mixed together by a kneader to obtain a paste. The paste was applied on a plastic film previously endowed with releasability, thereon covered with a polypropylene nonwoven fabric and pressure-contact transferred to obtain a plaster.
______________________________________Example 12 plaster______________________________________styrene-isoprene-styrene 15.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 5.0% by weight(trade name: Vistanex)liquid paraffin 23.0% by weightrosin ester derivative 42.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 10.0% by weightdiclofenac 5.0% by weight______________________________________
The components of the above prescription were mixed together by a kneader to obtain a paste. The paste was applied on a plastic film previously endowed with releasability, thereon covered with a polypropylene nonwoven fabric and pressure-contact transferred to obtain a plaster.
______________________________________Example 13 plaster______________________________________styrene-isoprene-styrene 18.0% by weightblock copolymer(trade name: Cariflex TR-1112)liquid paraffin 54.5% by weightrosin ester derivative 18.5% by weight(trade name: Foral 105)3-l-menthoxypropane-1,2-diol 6.0% by weightdiclofenac methyl ester 3.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 8.
______________________________________Example 14 plaster______________________________________styrene-isoprene-styrene 25.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 68.0% by weightrosin ester derivative 5.0% by weight(trade name: Ester Gum AA-G)3-l-menthoxypropane-1,2-diol 1.5% by weightketoprofen 0.5% by weight______________________________________
A plaster was obtained in the same manner as in Example 9.
______________________________________Example 15 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 43.5% by weightrosin ester derivative 30.5% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 3.0% by weightketoprofen 3.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 10.
______________________________________Example 16 plaster______________________________________styrene-isoprene-styrene 15.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutene 7.0% by weight(trade name: Vistanex)liquid paraffin 23.0% by weightrosin ester derivative 40.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 10.0% by weightketoprofen 5.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 11.
______________________________________Example 17 plaster______________________________________styrene-isoprene-styrene 28.0% by weightblock copolymer(trade name: Solprene 418)polybutene 5.0% by weightliquid paraffin 57.7% by weightrosin ester derivative 7.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 1.8% by weightflurbiprofen 0.5% by weight______________________________________
A plaster was obtained in the same manner as in Example 12.
______________________________________Example 18 plaster______________________________________styrene-isoprene-styrene 21.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 66.8% by weightrosin ester derivative 7.2% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 4.0% by weightflurbiprofen 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 9.
______________________________________Example 19 plaster______________________________________styrene-isoprene-styrene 21.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 45.0% by weightrosin ester derivative 20.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 9.0% by weightflurbiprofen 5.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 10.
______________________________________Example 20 plaster______________________________________styrene-isoprene-styrene 11.0% by weightblock copolymer(trade name: Cariflex TR-1107)styrene-isoprene-styreneblock copolymer 11.0% by weight(trade name: Cariflex TR-1111)liquid paraffin 44.0% by weightrosin ester derivative 26.0% by weight(trade name: Ester Gum AA-G)3-l-menthoxypropane-1,2-diol 7.0% by weightflurbiprofen 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 12.
______________________________________Example 21 plaster______________________________________styrene-isoprene-styrene 30.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 56.0% by weightrosin ester derivative 8.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 5.0% by weightloxoprofen 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 11.
______________________________________Example 22 plaster______________________________________styrene-isoprene-styrene 12.0% by weightblock copolymer(trade name: Cariflex TR-1111)liquid paraffin 28.0% by weightrosin ester derivative 40.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 12.0% by weightloxoprofen 8.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 11.
______________________________________Example 23 plaster______________________________________styrene-isoprene-styrene 21.0% by weightblock copolymer(trade name: Cariflex TR-1112)liquid paraffin 50.0% by weightrosin ester derivative 20.5% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 5.5% by weightloxoprofen 3.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 12.
______________________________________Example 24 plaster______________________________________styrene-isoprene-styrene 10.0% by weightblock copolymer(trade name: Cariflex TR-1111)liquid paraffin 43.0% by weightrosin ester derivative 35.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 10.0% by weightsodium loxoprofen 2.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 9.
______________________________________Example 25 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 47.0% by weightrosin ester derivative 21.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 9.0% by weightsodium loxoprofen 3.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 10.
______________________________________Example 26 plaster______________________________________styrene-isoprene-styrene 22.0% by weightblock copolymer(trade name: Cariflex TR-1107)polyisobutylene 5.0% by weight(trade name: Vistanex)liquid paraffin 52.0% by weightrosin ester derivative 12.0% by weight(trade name: Hercolyn D)3-l-menthoxypropane-1,2-diol 7.0% by weightloxoprofen 2.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 11.
______________________________________Example 27 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1111)liquid paraffin 38.0% by weightrosin ester derivative 30.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 8.0% by weightketorolac 4.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 9.
______________________________________Example 28 plaster______________________________________styrene-isoprene-styrene 28.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 57.5% by weightrosin ester derivative 9.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 4.5% by weightketorolac 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 11.
______________________________________Example 29 plaster______________________________________styrene-isoprene-styrene 21.0% by weightblock copolymer(trade name: Cariflex TR-1112)liquid paraffin 53.0% by weightrosin ester derivative 10.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 14.0% by weightketorolac tromethamine 2.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 12.
______________________________________Example 30 plaster______________________________________styrene-isoprene-styrene 33.0% by weightblock copolymer(trade name: Cariflex TR-1111)liquid paraffin 60.0% by weightrosin ester derivative 5.0% by weight(trade name: Foral 105)3-l-menthoxypropane-2,2-diol 1.5% by weightketorolac 0.5% by weight______________________________________
A plaster was obtained in the same manner as in Example 11.
______________________________________Example 31 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 5.0% by weight(trade name: Vistanex)liquid paraffin 55.0% by weightrosin ester derivative 10.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 8.0% by weightketoprofen 2.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 8.
______________________________________Example 32 plaster______________________________________styrene-isoprene-styrene 15.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 14.0% by weight(trade name: Vistanex)liquid paraffin 38.0% by weightrosin ester derivative 25.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-dioi 5.0% by weightketoprofen 3.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 9.
______________________________________Example 33 plaster______________________________________styrene-isoprene-styrene 22.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 8.0% by weight(trade name: Vistanex)liquid paraffin 48.0% by weightrosin ester derivative 14.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 8.0% by weightketorolac 2.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 10.
______________________________________Example 34 plaster______________________________________styrene-isoprene-styrene 15.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 12.0% by weight(trade name: Vistanex)liquid paraffin 27.0% by weightrosin ester derivative 38.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 4.0% by weightketorolac 4.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 10.
______________________________________Example 35 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 45.5% by weightrosin ester derivative 30.5% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 3.0% by weightfelbinac 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 10.
______________________________________Example 36 plaster______________________________________styrene-isoprene-styrene 15.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 14.0% by weight(trade name: Vistanex)liquid paraffin 38.0% by weightrosin ester derivative 26.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 5.0% by weightfelbinac 2.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 12.
______________________________________Example 37 plaster______________________________________styrene-isoprene-styrene 22.0% by weightblock copolymer(trade name: Cariflex TR-1107)polyisobutylene 5.0% by weight(trade name: Vistanex)liquid paraffin 52.0% by weightrosin ester derivative 12.0% by weight(trade name: Hercolyn D)3-l-menthoxypropane-1,2-diol 7.0% by weightfelbinac 2.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 11.
______________________________________Example 38 plaster______________________________________styrene-isoprene-styrene 28.0% by weightblock copolymer(trade name: Solprene 418)polybutene 5.0% by weightliquid paraffin 57.0% by weightrosin ester derivative 7.5% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 2.0% by weightsuprofen 0.5% by weight______________________________________
A plaster was obtained in the same manner as in Example 12.
______________________________________Example 39 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1111)liquid paraffin 40.0% by weightrosin ester derivative 34.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 4.0% by weightsuprofen 2.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 9.
______________________________________Example 40 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1107)polyisobutylene 5.0% by weight(trade name: Vistanex)liquid paraffin 45.0% by weightrosin ester derivative 20.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 9.0% by weightestradiol 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 8.
______________________________________Example 41 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 12.0% by weight(trade name: Vistanex)liquid paraffin 37.0% by weightrosin ester derivative 20.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 10.0% by weightestradiol 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 9.
______________________________________Example 42 plaster______________________________________styrene-isoprene-styrene 22.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 6.0% by weight(trade name: Vistanex)liquid paraffin 45.0% by weightrosin ester derivative 23.0% by weight(trade name: Foral 105)3-l-menthoxypropane-1,2-diol 3.0% by weightprogesterone 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 10.
______________________________________Example 43 plaster______________________________________styrene-isoprene-styrene 15.0% by weightblock copolymer(trade name: Cariflex TR-1107)polyisobutylene 10.0% by weight(trade name: Vistanex)liquid paraffin 39.0% by weightrosin ester derivative 30.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 5.0% by weightprogesterone 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 11.
______________________________________Example 44 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 5.0% by weight(trade name: Vistanex)liquid paraffin 47.0% by weightrosin ester derivative 17.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 10.0% by weightnorethisterone 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 12.
______________________________________Example 45 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1111)polyisobutylene 11.0% by weight(trade name: Vistanex)liquid paraffin 25.0% by weightrosin ester derivative 30.0% by weight(trade name: Ester Gum H)3-l-menthoxypropane-1,2-diol 13.0% by weightnorethisterone 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 10.
______________________________________Example 46 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1112)polyisobutylene 12.0% by weight(trade name: Vistanex)liquid paraffin 30.0% by weightrosin ester derivative 30.0% by weight(trade name: Foral 105)3-l-menthoxypropane-1,2-diol 7.0% by weighttestosterone 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 9.
______________________________________Example 47 plaster______________________________________styrene-isoprene-styrene 22.0% by weightblock copolymer(trade name: Cariflex TR-1107)polyisobutylene 5.0% by weight(trade name: Vistanex)liquid paraffin 45.0% by weightrosin ester derivative 22.0% by weight(trade name: KE-311)3-l-menthoxypropane-1,2-diol 5.0% by weighttestosterone 1.0% by weight______________________________________
A plaster was obtained in the same manner as in Example 12.
______________________________________Comparative Example 6 plaster______________________________________styrene-isoprene-styrene 20.0% by weightblock copolymer(trade name: Cariflex TR-1107)liquid paraffin 43.5% by weightpolyisobutylene 10.0% by weight(trade name: Vistanex)rosin ester derivative 21.5% by weight(trade name: KE-311)diclofenac 1.0% by weight______________________________________
The components of the above prescription were mixed by a mixer to obtain a paste. The paste was applied on a plastic film previously endowed with releasability, thereon covered with polyester fabric and pressure-contact transferred to obtain a plaster. The prescription of Comparative Example 6 was the same as that of Example 9 except that the former lacked in 3-l-menthoxy propane-1,2-diol as a solubilizer.
______________________________________Example 48 ointment______________________________________white vaseline 76.0% by weightglycerol monostearate 10.0% by weightbeef tallow 10.0% by weightsilicone oil 1.0% by weight3-l-menthoxypropane-1,2-diol 2.0% by weightflurbiprofen 1.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare an ointment comprising flurbiprofen.
______________________________________Example 49 ointment______________________________________white vaseline 76.95% by weightdiethyl sebacate 5.0% by weightspermaceti 5.0% by weightsodium polyoxyethylene- 4.0% by weightlauryletherphosphate2-hydroxy-4-methoxybenzophenone 1.0% by weightbutyl p-oxybenzoate 0.05% by weight3-l-menthoxypropane-1,2-diol 5.0% by weightketoprofen 3.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare an ointment comprising ketoprofen.
______________________________________Example 50 ointment______________________________________white vaseline 82.95% by weightisopropyl myristate 8.0% by weightspermaceti 3.0% by weightsodium polyoxyethylene- 2.0% by weightlauryletherphosphatebutyl p-oxybenzoate 0.05% by weight3-l-menthoxypropane-1,2-diol 3.0% by weightindomethacin 1.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare an ointment comprising indomethacin.
______________________________________Example 51 gel______________________________________carboxyvinyl polymer 2.0% by weighthydroxypropylcellulose 2.0% by weightethanol 37.0% by weightpurified water 33.0% by weightpropylene glycol 15.0% by weightdiisopropyladipate 2.0% by weightdiisopropanolamine 2.5% by weight2-hydroxy-4-methoxybenzophenone 0.5% by weight3-l-menthoxypropane-1,2-diol 3.0% by weightketoprofen 3.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a gel comprising ketoprofen.
______________________________________Example 52 gel______________________________________carboxyvinyl polymer 1.5% by weighthydroxypropylcellulose 2.0% by weightethanol 17.0% by weightpurified water 35.3% by weightpropylene glycol 30.0% by weightpropylene carbonate 10.0% by weighttriethanolamine 0.2% by weight3-l-menthoxypropane-1,2-diol 3.0% by weightindomethacin 1.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a gel comprising indomethacin.
______________________________________Example 53 gel______________________________________carboxyvinyl polymer 1.0% by weightethanol 35.0% by weightpurified water 49.0% by weightpropylene glycol 10.0% by weightdiisopropanolamine 1.0% by weight3-l-menthoxypropane-1,2-diol 3.0% by weightflurbiprofen 1.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a gel comprising flurbiprofen.
______________________________________Example 54 cream______________________________________liquid paraffin 10.0% by weightmiddle chain triacylglycerol 5.0% by weightpolyethylene glycol monostearate 3.0% by weightglycerol 5.0% by weightcarboxyvinyl polymer 1.0% by weightdiisopropanolamine 0.4% by weightmethyl p-oxybenzoate 0.2% by weightindomethacin 1.0% by weight3-l-menthoxypropane-1,2-diol 5.0% by weightpurified water residual quantity______________________________________
The above components were mixed together under agitation, thereby to prepare a cream comprising indomethacin.
______________________________________Example 55 cream______________________________________carboxyvinyl polymer 1.0% by weightisopropyl myristate 5.0% by weightethanol 5.0% by weightpolyethylene glycol monostearate 1.0% by weightcoconut oil fatty acid 3.0% by weightdiethanolamidemethyl p-oxybenzoate 0.2% by weight2-hydroxy-4-methoxybenzophenone 0.8% by weightketoprofen 3.0% by weight3-l-menthoxypropane-1,2-diol 7.0% by weightpurified water residual quantity______________________________________
The above components were mixed together under agitation, thereby to prepare a cream comprising ketoprofen.
______________________________________Example 56 cream______________________________________carboxyvinyl polymer 1.0% by weightglycerol 10.0% by weightethanol 5.0% by weightdiisopropanolamine 0.4% by weightmedium chain triglyceride 3.0% by weightflurbiprofen 1.0% by weight3-l-menthoxypropane-1,2-diol 5.0% by weightpurified water residual quantity______________________________________
The above components were mixed together under agitation, thereby to prepare a cream comprising flurbiprofen.
______________________________________Example 57 gel-type cream______________________________________carboxyvinyl polymer 1.0% by weightisopropyl myristate 10.0% by weightethanol 5.0% by weightpolyethyleneglycol monostearate 1.0% by weightmethyl p-oxybenzoate 0.2% by weightcoconut oil fatty acid 3.0% by weightdiethanolamideketoprofen 3.0% by weight3-l-menthoxypropane-1,2-diol 3.0% by weightpurified water residual quantity______________________________________
The above components were mixed together under agitation, thereby to prepare a gel-type cream comprising ketoprofen.
______________________________________Example 58 gel-type cream______________________________________carboxyvinyl polymer 1.0% by weightisopropyl palmitate 9.0% by weightdiethyl sebacate 9.0% by weightpolyoxyethylene cetylether 2.0% by weightpropylene carbonate 7.0% by weightmethyl p-oxybenzoate 0.2% by weightsodium hydroxide 0.1% by weightindomethacin 1.0% by weight3-l-menthoxypropane-1,2-diol 5.0% by weightpurified water residual quantity______________________________________
The above components were mixed together under agitation, thereby to prepare a gel-type cream comprising indomethacin.
______________________________________Example 59 gel-type cream______________________________________carboxyvinyl polymer 1.5% by weightcetyl isooctanoate 10.0% by weightethanol 5.0% by weightpolyethyleneglycol monostearate 1.0% by weightmethyl p-oxybenzoate 0.2% by weightcoconut oil fatty acid 3.0% by weightdiethanolamideflurbiprofen 3.0% by weight3-l-menthoxypropane-1,2-diol 5.0% by weightpurified water residual quantity______________________________________
The above components were mixed together under agitation, thereby to prepare a gel-type cream comprising flurbiprofen.
______________________________________Example 60 gel-type cream______________________________________carboxyvinyl polymer 1.0% by weightisopropyl myristate 6.0% by weightdiethyl sebacate 5.0% by weightpolyoxyethylene cethylether 2.0% by weightpropylene carbonate 3.0% by weightmethyl p-oxybenzoate 0.2% by weightsodium hydroxide 0.1% by weightketorolac 3.0% by weight3-l-menthoxypropane-1,2-diol 7.0% by weightpurified water residual quantity______________________________________
The above components were mixed together under agitation, thereby to prepare a gel-type cream comprising ketorolac.
______________________________________Example 61 lotion______________________________________ethanol 57.0% by weightpurified water 34.0% by weightpropylene glycol 5.0% by weight3-l-menthoxypropane-1,2-diol 3.0% by weightketoprofen 1.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a lotion comprising ketoprofen.
______________________________________Example 62 lotion______________________________________ethanol 38.0% by weightpurified water 50.0% by weightpropylene glycol 6.0% by weight3-l-menthoxypropane-1,2-diol 5.0% by weightindomethacin 1.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a lotion comprising indomethacin.
______________________________________Example 63 lotion______________________________________ethanol 30.0% by weightpurified water 50.2% by weightpropylene glycol 10.0% by weightmethylcellulose 0.8% by weight3-l-menthoxypropane-1,2-diol 7.0% by weightflurbiprofen 2.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a lotion comprising flurbiprofen.
______________________________________Example 64 reserver-type patch______________________________________(1) a backing layer polyester-type film(2) a drug reserving layer 4 g of the following gel components were enclosed in the drug reserving layer. ketorolac 5.0% by weight 3-l-menthoxypropane-1,2-diol 3.0% by weight carboxyvinyl polymer 2.0% by weight propylene glycol 30.0% by weight triethyl citrate 19.0% by weight purified water 39.4% by weight 2-hydroxy-4-methoxybenzophenone 0.5% by weight diisopropanolamine 1.1% by weight(3) a drug releasing layer Juragard (trade name, a product of Polyplastic Co., Ltd.)(4) a pressure-sensitive silicon-type adhesive adhesive layer______________________________________
This reserver-type patch consisted of the above (1)-(4) layers and a releasing liner was put on the pressure-sensitive adhesive surface thereby to obtain a laminate.
______________________________________Example 65 reserver-type patch______________________________________(1) a backing layer polyester-type film(2) a drug reserving layer 4 g of the following gel composition were enclosed in the drug reserving layer. ketoprofen 3.0% by weight 3-l-menthoxypropane-1,2-diol 5.0% by weight liquid paraffin 70.0% by weight stearyl alcohol 20.0% by weight d-limonene 2.0% by weight(3) a drug releasing layer Cotran (tradename, a product of 3M Co., Ltd.(4) a pressure-sensitive polyisobutylene- adhesive layer type adhesive______________________________________
This reserver-type patch consisted of the above (1)-(4) layers and a releasing liner was put on the pressure-sensitive adhesive surface thereby to obtain a laminate.
______________________________________Example 66 reserver-type patch______________________________________(1) a backing layer Aluminum laminating polyester film(2) a drug reserving layer 4 g of the following gel composition were enclosed in the drug reserving layer. ketorolac 5.0% by weight 3-l-menthoxypropane-1,2-diol 10.0% by weight silicon 80.0% by weight glycerol monolaurate 5.0% by weight(3) a drug releasing layer Cotran(4) a pressure-sensitive silicon-type adhesive adhesive layer (around a support)______________________________________
This reserver-type patch consisted of the above (1)-(4) layers and a releasing liner was put on the pressure-sensitive adhesive surface thereby to obtain a laminate.
______________________________________Example 67 reserver-type patch______________________________________(1) a backing layer Aluminum laminating polyester film(2) a drug reserving layer 4 g of the following gel composition were enclosed in the drug reserving layer. ketorolac 5.0% by weight 3-l-menthoxypropane-1,2-diol 10.0% by weight silicon 80.0% by weight glycerol monolauric acid 5.0% by weight(3) a drug releasing layer Cotran(4) a pressure-sensitive silicon-type adhesive adhesive layer (around a support)______________________________________
This reserver-type patch consisted of the above (1)-(4) layers and a releasing liner was put on the pressure-sensitive adhesive surface to obtain a laminate.
______________________________________Example 68 reserver-type patch______________________________________(1) a backing layer Aluminum laminating polyester film(2) a drug reserving layer 4 g of the following gel composition were enclosed in the drug reserving layer. tulobuterol hydrochloride 5.0% by weight 3-l-menthoxypropane-1,2-diol 5.0% by weight stearyl alcohol 10.0% by weight cetyl alcohol 10.0% by weight behenyl alcohol 10.0% by weight propylene glycol 20.0% by weight 1,3-butylene glycol 35.0% by weight lauryl alcohol 5.0% by weight(3) a drug releasing layer Cotran(4) a pressure-sensitive silicon-type adhesive adhesive layer (around a support)______________________________________
This reserver-type patch consisted of the above (1)-(4) layers and a releasing liner was put on the pressure-sensitive adhesive surface to obtain a laminate.
______________________________________Example 69 liniment______________________________________ethanol 45.0% by weight2-hydroxy-4-methoxybenzophenone 0.6% by weightdiisopropyl adipate 30.0% by weight.alpha.-tocopherol 1.0% by weighthydroxypropylcellulose 1.5% by weightketoprofen 2.0% by weight3-l-menthoxypropane-1,2-diol 4.0% by weightpurified water 15.9% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a lotion comprising ketoprofen.
______________________________________Example 70 liniment______________________________________propyleneglycol 10.0% by weight2-hydroxy-4-methoxybenzophenone 0.2% by weightpolyethyleneglycol 10.0% by weightmonolauratecrotamiton 0.5% by weightacetone 18.0% by weightethyl alcohol 20.0% by weightethanol 28.8% by weightketoprofen 0.5% by weight3-l-menthoxypropane-1,2-diol 2.0% by weightpurified water 10.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a liniment comprising ketoprofen.
______________________________________Example 71 liniment______________________________________polyethyleneglycol 400 45.0% by weight2-hydroxy-4-methoxybenzophenone 0.5% by weight.alpha.-tocopherol 1.0% by weightisopropylalcohol 31.5% by weightethanol 40.0% by weightketorolac 5.0% by weight3-l-menthoxypropane-1,2-diol 7.0% by weightpurified water 7.0% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a liniment comprising ketorolac.
______________________________________Example 72 liniment______________________________________polyethyleneglycol 15.0% by weightmonolaurate2,2-hydroxy-4-methoxybenzophenone 0.7% by weightdiisopropyl adipate 4.0% by weight.alpha.-tocopherol 1.0% by weight8-acetylsucrose denatured alcohol 49.6% by weightketorolac 3.0% by weight3-l-menthoxypropane-1,2-diol 5.0% by weightpurified water 21.7% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a liniment comprising ketorolac.
EXAMPLE 73
Aerosol
4.5% by weight of camphor, 4.0% by weight of 3-l-menthoxypropane-1,2-diol, 3.0% by weight of ketoprofen and 1.0% by weight of 2-hydroxy-4-methoxybenzophenone were solubilized in 32.5% by weight of ethanol, incorporated with 26.0% by weight of water, charged into an aerosol container and then incorporated with 4.0% by weight of talc to prepare a pharmaceutical solution, after which a mixed propellant composed of 13.0% by weight of dimethyl ether and 12.0% by weight of liquefied petroleum gas was injected into the container, thereby to obtain an anti-inflammatory and analgetic aerosol. The above weight percentages were respectively based on the whole quantity.
EXAMPLE 74
Aerosol
4.5% by weight of camphor, 0.4% by weight of diphenhydramine, 5.0% by weight of 3-l-menthoxypropane-1,2-diol, 1.0% by weight of ketorolac and 1.0% by weight of .alpha.-tocopherol were solubilized in 30.1% by weight of ethanol, incorporated with 24.0% by weight of water to the obtained solution, and then charged into an aerosol container, after which a mixed propellant composed of 25.0% by weight of dimethyl ether and 9.0% by weight of liquefied petroleum gas was injected into the container, thereby to obtain an anti-inflammatory and analgetic aerosol, wherein the ratios were respectively based on the whole quantity.
______________________________________Example 75 creamy-type pack______________________________________liquid paraffin 10.0% by weightcetanol 1.0% by weightsorbitan monostearate 3.0% by weightPOE (20) sorbitan monostearate 3.0% by weight1,3-butylene glycol 5.0% by weightglycerol 3.0% by weightmethyl paraben 0.2% by weightstearyl glycyrrhetinate 0.1% by weight3-l-menthoxypropane-1,2-diol 1.0% by weightpurified water 73.7% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a cream-type pack.
______________________________________Example 76 clay-type pack______________________________________kaolin 20.0% by weighttalc 8.0% by weightglycerol 3.0% by weightpropylene glycol 3.0% by weightcarboxymethyl cellulose 0.3% by weightPOE (20) sorbitan monooleate 2.0% by weightmethyl paraben 0.1% by weightL-ascorbyl stearate 0.2% by weight3-l-menthoxypropane-1,2-diol 3.0% by weightpurified water 60.4% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a clay-type pack.
______________________________________Example 77 foam-type pack______________________________________stearic acid 5.0% by weightbehenic acid 5.0% by weightcetanol 1.0% by weightsqualane 4.0% by weightglycerol 15.0% by weightPOE (40) monostearate 1.0% by weightethyl paraben 0.1% by weightL-ascorbyl palmitate 0.05% by weight3-l-menthoxypropane-1,2-diol 0.5% by weightpurified water 68.35% by weight______________________________________
The above components were mixed together under agitation, thereby to prepare a liquid. Thereafter the liquid was injected with a liquefied petroleum gas into a container to obtain a foam-type pack.
______________________________________ pressure-sensitive ad-Example 78 hesive-type sheet pack______________________________________gelatin 8.0% by weightglycerol 25.0% by weightsorbitol 7.0% by weightsodium polyacrylate 2.0% by weightpolyvinyl alcohol 2.0% by weightaluminium hydroxide 1.0% by weightmethyl paraben 0.05% by weightisopropyl methylphenol 0.01% by weight3-l-menthoxypropane-1,2-diol 0.005% by weightpurified water 54.935% by weight______________________________________
The above components were mixed together under agitation, thereby to obtain a paste. The paste was spread on a nonwoven fabric, covered thereon with a release film to obtain a laminate. The laminate was cut into pieces each having a predetermined form to obtain adhesive-type sheet packs.
______________________________________ impregnation-typeExample 78 sheet pack______________________________________glycerol 10.0% by weight1,3-butylene glycol 10.0% by weightsodium hyaluroniate 0.1% by weightmethyl paraben 0.1% by weightglycyrrhizinic acid 0.01% by weight3-l-menthoxypropane-1,2-diol 0.05% by weightpurified water 79.74% by weight______________________________________
The above components were mixed together under agitation, thereby to obtain a mixture. The mixture was impregnated into a nonwoven fabric, covered thereon with a release film to obtain a laminate. The laminate was cut into pieces each having a predetermined form to obtain impregnation-type sheet packs.
______________________________________Example 80 peel-off pack______________________________________polyvinyl alcohol 20.0% by weightcarboxymethyl cellulose 3.0% by weighttitanium oxide 8.0% by weight1,3-butylene glycol 5.0% by weightsqualane 3.0% by weightPOE (10) nonylphenyl ether 0.5% by weightmethyl paraben 0.1% by weightcalciferol 0.01% by weight3-l-menthoxypropane-1,2-diol 0.1% by weightpurified water 60.29% by weight______________________________________
The above components were mixed together under agitation, thereby to obtain peel-off packs.
COMPARATIVE EXAMPLE 7
Cream-type Pack
The procedure of Example 75 was followed except that the 3-l-menthoxypropane-1,2-diol was not used, thereby to obtain a cream-type pack.
COMPARATIVE EXAMPLE 8
Adhesive-type Sheet Pack
The procedure of Example 78 was followed except that the 3-l-menthoxypropane-1,2-diol was not used, thereby to obtain a adhesive-type sheet pack.
TEST EXAMPLE 1
The plasters of Example 7 and Comparative Examples 4 and 5 were stored at 5.degree. C. for two weeks, while they were observed with the lapse of time to find whether the drug crystallized or not. The results are given in Table 1.
TABLE 1______________________________________Sample initial 1 day 3 days 7 days 14 days______________________________________plaster .smallcircle. .smallcircle. .smallcircle. .smallcircle. .smallcircle.of Ex. 7plaster x x x x xof Comp.Ex. 4plaster .smallcircle. x x x xof Comp.Ex. 5______________________________________ .smallcircle.: no crystallization was found x: crystallization was found
As apparent from the above results, the plaster of Example 7 containing 3-l-menthoxypropane-1,2-diol as the solubilizer contained clonidine in its solubilized state in the base even after the lapse of two weeks, while the plaster of Comparative Example 4 containing no solubilizer and that of Comparative Example 5 containing isopropyl myristate suffered from the crystallization of clonidine in their respective bases. Thus, the above results supported the usefulness of 3-l-menthoxypropane-1,2-diol as the solubilizer for clonidine.
TEST EXAMPLE 2
(Adhesion Test)
The poultices of Examples 1 to 4 and Comparative Examples 1 to 3 were examined for their adhesion and changes thereof time according to the Nichiban Rolling Ball method. This method is such that a ball is so rolled along a poultice sample from a predetermined height at an angle of 30.degree. C. as to draw a sine curve, to measure a distance from a point where the rolling ball reaches the smple to a point where it stops rolling. Accordingly, a shorter distance of roll or a bigger ball means a more excellent adhesion. In this test, a poultice sample having a length of 140 mm was spread with its adhesive side up and a stainless steel ball (20/32 inch, JIS) was rolled along the sample to determine the distance of roll of the ball. The results are given in Table 2.
TABLE 2______________________________________Pressure- After storagesensitive Initial for 6 months atAdhesive tape adhesion (mm) 40.degree. C. (mm)______________________________________Ex. 1 50 48Ex. 2 30 33Ex. 3 35 38Ex. 4 43 41Comp. Ex. 1 98 95Comp. Ex. 2 78 82Comp. Ex. 3 passed through passed through______________________________________
As apparent from the above results, the polutices of Examples 1 to 4 exhibited excellent adhesion and the adhesion did not change even after the lapse of time.
TEST EXAMPLE 3
(Test on Safety for the Skin)
The poultices of Examples 1 to 4 and Comparative Examples 1 to 3 were examined for safety for the skin.
The safety of each poultice for the skin was determined by 25 healthy male and female subjects according to the 48-hour closed patch test. The change in the skin of each subject was determined by observation 1 and 24 hours after the peeling of the patch, and the irritativeness of the poultice was evaluated according to the following criteria. The results are given in Tables 3 and 4.
-: no change in the skin
.+-.: slight rubefaction
+: clear rubefaction
++: heavy contact dermatitis
TABLE 3______________________________________Timewhich has Rate (%) ofelapsed positiveafter Judgement Total reactionpeeling Sample ++ + .+-. - (subjects) (.+-., + and ++)______________________________________1 hr Ex. 1 0 0 0 25 25 0.01 hr Ex. 2 0 0 1 24 25 4.01 hr Ex. 3 0 0 0 25 25 0.01 hr Ex. 4 0 0 0 25 25 0.01 hr Comp. Ex. 1 0 0 2 23 25 8.01 hr Comp Ex. 2 0 0 1 24 25 4.01 hr Comp Ex. 3 0 0 3 22 25 12.0______________________________________
TABLE 4______________________________________Timewhich has Rate (%) ofelapsed positiveafter Judgement Total reactionpeeling Sample ++ + .+-. - (subjects) (.+-., + and ++)______________________________________24 hrs Ex. 1 0 0 0 25 25 0.024 hrs Ex. 2 0 0 0 25 25 0.024 hrs Ex. 3 0 0 0 25 25 0.024 hrs Ex. 4 0 0 0 25 25 0.024 hrs Comp. Ex. 1 0 0 1 24 25 4.024 hrs Comp Ex. 2 0 0 0 25 25 0.024 hrs Comp Ex. 3 0 0 1 24 25 4.0______________________________________
As apparent from the above results, the poultices of Examples 1 to 4 exhibited extremely high safety for the skin.
TEST EXAMPLE 4
(Test on Human Percutaneous Absorption)
The poultices of Example 4 and Comparative Example 2 were each die-cut into samples (3.times.3 cm.sup.2). These samples were applied to the upper backs of eight healthy subjects respectively. After 8 hours, the samples were peeled and examined for the amount of ketoprofen remaining in the peeled samples by HPLC (high performance liquid chromatography). The calculation of human absorption rate, the determination of amount of the remaining ketoprofen and HPLC were conducted as follows:
(1) human absorption rate
=(1--remaining amount/initial content).times.100
(2) determination of amount of residue of ketoprofen Each peeled sample was extracted with 70 ml of methanol under reflux and the extract was diluted with methanol to 100 ml. The resulting dilution was used as the sample for HPLC.
(3) Conditions of HPLC
mobile phase; 0.2% aqueous solution of acetic acid:acetonitrile=55:45
detection wavelength; 254 nm
column; TSK gel ODS-80TM
flow rate; 1.0 .mu.l/min.
TABLE 5______________________________________ Human absorption rate (%)______________________________________Ex. 4 12.7Comp. Ex. 2 5.0______________________________________
As shown in Table 5, the poultice of Example 4 containing 3-l-menthoxypropane-1,2-diol as the solubilizer exhibited a higher absorption rate than that of the poultice of Comparative Example 2.
TEST EXAMPLE 5
The plasters of Example 9 and Comparative Example 6 were stored at 5.degree. C., while they were observed with the lapse of time to determine whether crystallization occurred or not. The results are given in Table 6.
TABLE 6______________________________________Sample initial 1 day 3 days 7 days 14 days______________________________________Ex. 9 .smallcircle. .smallcircle. .smallcircle. .smallcircle. .smallcircle.Comp. Ex. 6 .smallcircle. .smallcircle. x x x______________________________________ .smallcircle.: no crystallization was found x: crystallization was found
As apparent from the results given in Table 6, the plaster of Example 9 contained diclofenac in a solubilized state in the base even after the lapse of time, though that of Comparative Example 6 containing no solubilizer suffered from the crystallization of diclofenac. Thus, the above results supported the usefulness of 3-l-menthoxypropane-1,2-diol as the solubilizer for diclofenac.
TEST EXAMPLE 6
(Test on Human Pecutaneous Absorption)
The plasters of Example 9 and Comparative Example 6 were each die-cut into samples (3.times.3 cm.sup.2). These samples were applied to the upper backs of six healthy subjects respectively. After 8 hours, the samples were peeled and examined for the residual amount of diclofenac by HPLC. The calculation of human absorption rate, the determination of residual amount of diclofenac and HPLC were conducted as follows:
(1) human absorption rate
=(1--residual amount/initial content).times.100
(2) determination of residual amount of diclofenac:
Each peeled sample was subjected to ultrasonic extraction with 30 ml of tetrahydrofuran for 2 hours and the extract was diluted with tetrahydrofuren to 50 ml. The resulting dilution was used as the sample for HPLC.
(3) Conditions of HPLC
mobile phase; 0.2% aqueous solution of acetic acid:acetonitrile=1:1
detection wavelength; 275 nm
column; TSK gel ODS-80TM
flow rate; 1.0 .mu.l/min.
The results are given in FIGURE 1. As apparent from FIGURE 1, the plaster of Example 9 exhibited a significantly enhanced absorption rate as compared with that of Comparative Example 6. In other words, the plaster of Example 9 could contain diclofenac in a solubilized state by virtue of the solubilizability of 3-l-menthoxypropane-1,2-diol thereby to give excellent release of diclofenac.
TEST EXAMPLE 7
The packs of Examples 75 and 78 and Comparative Examples 7 and 8 were stored at 5.degree. C. for two weeks, while they were observed with the lapse of time to determine whether the fat-soluble powder crystallized or not. The results are given in Table 7.
TABLE 7______________________________________initial 1 day 3 days 7 days 14 days______________________________________Ex. 75 .smallcircle. .smallcircle. .smallcircle. .smallcircle. .smallcircle.Ex. 78 .smallcircle. .smallcircle. .smallcircle. .smallcircle. .smallcircle.Comp. Ex. 7 x x x x xComp. Ex. 8 .smallcircle. x x x x______________________________________ .smallcircle.: no crystallization was found x: crystallization was found
The above results supported the usefulness of 3-l-menthoxypropane-1,2-diol as the solubilizer for a fat-soluble powder.
TEST EXAMPLE 8
The packs of Example 75 and Comparative Example 7 were examined organoleptically by ten female subjects. The results are given in Table 8.
TABLE 8______________________________________ Ex. 75 Comp. Ex. 7______________________________________Odor observed 0 0 not observed 10 10Refreshing observed 10 0effect not observed 0 10Irritation observed 0 0to the skin not observed 10 10Stickiness observed 0 1 not observed 10 9Roughness observed 1 8 not observed 9 2______________________________________
It can be understood from the above results that the pack of Example 75 has refreshing or refrigerant effect and is freed from the crystallization of a fat-soluble powder thereby to be excellent in feelings in use.
Industrial Applicability
According to the present invention, 3-l-menthoxypropane-1,2-diol which has been used as a refrigerant is used as a solubilizer for a pharmaceutically effective ingredient and this compound exhibits high solubilizability for a pharmaceutically effective ingredient and is excellent in safety, stability and compatibility. Accordingly, a percutaneously absorbable preparation (which is one of external preparations) containing said compound is improved in the release of a pharmaceutically effective ingredient from the base and the pecutaneous absorption of the effective agent. Further, such a preparation causes little side effects such as contact dermatitis even when applied repeatedly and is not irritant to the skin thereby to be extremely safe. Furthermore, the preparation is odorless and can impart comfortable refreshing refrigeration to the skin.
Accordingly, the external preparation of the present invention is suited for percutaneously absorbable preparations and packs, thus having high industrial applicability.

Number	Date	Country
0080148	Jun 1983	EPX
63-264522	Nov 1988	JPX

Solubilizer and external preparations containing the same

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (1)

PCT Information

US Referenced Citations (1)

Foreign Referenced Citations (2)

Non-Patent Literature Citations (1)